Jonathan Esensten, MD, PhD

Title(s)Associate Adjunct Professor, Office of the CEO
Address1855 Folsom Street, #001
San Francisco CA 94103
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoM.D.2012 Medicine
    University of California, San FranciscoPh.D.2010 Graduate Division (Biomedical Sciences)
    University of California, San FranciscoResidency, Clinical Pathology2016Laboratory Medicine
    University of California, San FranciscoFellowship, Transfusion Medicine and Blood Banking2015Laboratory Medicine
    Collapse Awards and Honors
    University of California, San Francisco2016  - 2019Leukemia and Lymphoma Society Fellow
    San Francisco General Hospital2013  - 2013Krevans Award in Laboratory Medicine
    University of California, San Francisco2010  - 2010Alpha Omega Alpha Honor Society

    Collapse Overview 
    Collapse Overview
    Dr. Jonathan Esensten leads an experimental cellular therapy process development and manufacturing group. His group focusses on improving techniques for manufacturing T cell based therapies for patients with autoimmune disease, solid organ transplant, and cancer. He was a Leukemia and Lymphoma Society Fellow in the laboratory of Dr. Wendell Lim. He is co-director of the clinical Regulatory T Cell Manufacturing Group. He is also Medical Director of the UCSF HICTF and GMP Facility. He completed residency in clinical pathology and fellowship in transfusion medicine and blood banking at UCSF.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Development of a robotic cluster for automated and scalable cell therapy manufacturing. Cytotherapy. 2024 Mar 1. Melocchi MA, Schmittlein SB, Jones JA, Ainane AY, Rizvi RA, Chan CD, Dickey DE, Pool PK, Harsono HK, Szymkiewicz SD, Scarfogliero SU, Bhatia BV, Sivanantham SA, Kreciglowa KN, Hunter HA, Gomez GM, Tanner TA, Uboldi UM, Batish BA, Balcerek BJ, Kutova-Stoilova KM, Paruthiyil PS, Acevedo AL, Stadnitskiy SR, Carmichael CS, Aulbach AH, Hewitt HM, Du Jeu DX, di Robilant dB, Parietti PF, Esensten EJ. .
      View in: Publisher Site   Mentions:
    2. Selective decrease of donor-reactive Tregs after liver transplantation limits Treg therapy for promoting allograft tolerance in humans. Sci Transl Med. 2022 11 02; 14(669):eabo2628. Tang Q, Leung J, Peng Y, Sanchez-Fueyo A, Lozano JJ, Lam A, Lee K, Greenland JR, Hellerstein M, Fitch M, Li KW, Esensten JH, Putnam AL, Lares A, Nguyen V, Liu W, Bridges ND, Odim J, Demetris AJ, Levitsky J, Taner T, Feng S. PMID: 36322627.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    3. High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails. Nat Biotechnol. 2023 04; 41(4):521-531. Shy BR, Vykunta VS, Ha A, Talbot A, Roth TL, Nguyen DN, Pfeifer WG, Chen YY, Blaeschke F, Shifrut E, Vedova S, Mamedov MR, Chung JJ, Li H, Yu R, Wu D, Wolf J, Martin TG, Castro CE, Ye L, Esensten JH, Eyquem J, Marson A. PMID: 36008610; PMCID: PMC10065198.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    4. Polyclonal Regulatory T Cell Manufacturing Under cGMP: A Decade of Experience. Front Immunol. 2021; 12:744763. Balcerek J, Shy BR, Putnam AL, Masiello LM, Lares A, Dekovic F, Acevedo L, Lee MR, Nguyen V, Liu W, Paruthiyil S, Xu J, Leinbach AS, Bluestone JA, Tang Q, Esensten JH. PMID: 34867967; PMCID: PMC8636860.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsPHPublic Health
    5. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. JCI Insight. 2021 09 22; 6(18). Dong S, Hiam-Galvez KJ, Mowery CT, Herold KC, Gitelman SE, Esensten JH, Liu W, Lares AP, Leinbach AS, Lee M, Nguyen V, Tamaki SJ, Tamaki W, Tamaki CM, Mehdizadeh M, Putnam AL, Spitzer MH, Ye CJ, Tang Q, Bluestone JA. PMID: 34324441; PMCID: PMC8492314.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCellsCTClinical Trials
    6. Characteristics of High-Titer Convalescent Plasma and Antibody Dynamics After Administration in Patients With Severe Coronavirus Disease 2019. Open Forum Infect Dis. 2021 Aug; 8(8):ofab385. Bainbridge ED, Hsue PY, Esensten JH, Lynch KL, Hendrickson CM, Doernberg SB, Fung M, Chin-Hong P, Di Germanio C, Norris PJ, Simmons G, Glidden DV, Luetkemeyer AF. PMID: 34405093; PMCID: PMC8344822.
      View in: PubMed   Mentions: 3  
    7. Outcomes after ultramassive transfusion in the modern era: An Eastern Association for the Surgery of Trauma multicenter study. J Trauma Acute Care Surg. 2021 07 01; 91(1):24-33. Matthay ZA, Hellmann ZJ, Callcut RA, Matthay EC, Nunez-Garcia B, Duong W, Nahmias J, LaRiccia AK, Spalding MC, Dalavayi SS, Reynolds JK, Lesch H, Wong YM, Chipman AM, Kozar RA, Penaloza L, Mukherjee K, Taghlabi K, Guidry CA, Seng SS, Ratnasekera A, Motameni A, Udekwu P, Madden K, Moore SA, Kirsch J, Goddard J, Haan J, Lightwine K, Ontengco JB, Cullinane DC, Spitzer SA, Kubasiak JC, Gish J, Hazelton JP, Byskosh AZ, Posluszny JA, Ross EE, Park JJ, Robinson B, Abel MK, Fields AT, Esensten JH, Nambiar A, Moore J, Hardman C, Terse P, Luo-Owen X, Stiles A, Pearce B, Tann K, Abdul Jawad K, Ruiz G, Kornblith LZ. PMID: 34144557; PMCID: PMC8243874.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    8. Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent Plasma. Am J Clin Pathol. 2021 Mar 15; 155(4):515-521. Balcerek J, Trejo E, Levine K, Couey P, Kornberg ZV, Rogine C, Young C, Li PJ, Shy BR, Taylor JE, Bakhtary S, Friedlander T, Lynch KL, Bern C, Esensten JH. PMID: 33399201; PMCID: PMC7929413.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Magnitude and Kinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Responses and Their Relationship to Disease Severity. Clin Infect Dis. 2021 01 27; 72(2):301-308. Lynch KL, Whitman JD, Lacanienta NP, Beckerdite EW, Kastner SA, Shy BR, Goldgof GM, Levine AG, Bapat SP, Stramer SL, Esensten JH, Hightower AW, Bern C, Wu AHB. PMID: 33501951; PMCID: PMC7454426.
      View in: PubMed   Mentions: 128     Fields:    Translation:HumansCells
    10. Processing laboratory considerations for multi-center cellular therapy clinical trials: a report from the Consortium for Pediatric Cellular Immunotherapy. Cytotherapy. 2021 02; 23(2):157-164. Lindgren C, Leinbach A, Annis J, Tanna J, Zhang N, Esensten JH, Hanley PJ. PMID: 33189573; PMCID: PMC7855775.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    11. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. Clin Infect Dis. 2020 Jul 14. Lynch KL, Whitman JD, Lacanienta NP, Beckerdite EW, Kastner SA, Shy BR, Goldgof GM, Levine AG, Bapat SP, Stramer SL, Esensten JH, Hightower AW, Bern C, Wu AHB. PMID: 32663256; PMCID: PMC7454426.
      View in: PubMed   Mentions:    Fields:    
    12. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. medRxiv. 2020 Jun 9; 2020.06.03.20121525. Lynch LK, Whitman WJ, Lacanienta LN, Beckerdite BE, Kastner KS, Shy SB, Goldgof GG, Levine LA, Bapat BS, Stramer SS, Esensten EJ, Hightower HA, Bern BC, Wu WA. .
      View in: Publisher Site   Mentions:
    13. Effect of combined low dose IL-2 and polyclonal Tregs infusion in Type 1 Diabetes patients. The Journal of Immunology. 2020 May 1; 204(1_Supplement):224.49-224.49. Dong DS, Mowery MC, Hiam HK, Herold HK, Gitelman GS, Esensten EJ, Liu LW, Lares LA, Nguyen NV, Lee LM, Leinbach LA, Ye YJ, Tang TQ, Bluestone BJ. .
      View in: Publisher Site   Mentions:
    14. 253-LB: Effect of Combined Low Dose IL-2 plus Polyclonal Tregs in Type 1 Diabetes Patients. Diabetes. 2019 Jun 1; 68(Supplement 1):253-lb. DONG DS, MOWERY MC, HEROLD HK, GITELMAN GS, ESENSTEN EJ, LIU LW, LARES LA, LEINBACH LA, LEE LM, NGUYEN NV, PUTNAM PA, YE YJ, TANG TQ, BLUESTONE BJ. .
      View in: Publisher Site   Mentions:
    15. Development of a large-scale H3.3K27M-specific TCR-transduced T cell manufacturing method for adoptive cell therapy in HLA-A2+ patients with diffuse midline glioma. Cytotherapy. 2019 May 1; 21(5):s36. Okada OK, Nguyen NA, Watchmaker WP, Xu XJ, Ramsdell RF, Esensten EJ, Butterfield BL, Okada OH. .
      View in: Publisher Site   Mentions:
    16. Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier. J Allergy Clin Immunol. 2018 12; 142(6):1710-1718. Esensten JH, Muller YD, Bluestone JA, Tang Q. PMID: 30367909.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansAnimalsCells
    17. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature. 2018 07; 559(7714):405-409. Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, Hiatt J, Saco J, Krystofinski P, Li H, Tobin V, Nguyen DN, Lee MR, Putnam AL, Ferris AL, Chen JW, Schickel JN, Pellerin L, Carmody D, Alkorta-Aranburu G, Del Gaudio D, Matsumoto H, Morell M, Mao Y, Cho M, Quadros RM, Gurumurthy CB, Smith B, Haugwitz M, Hughes SH, Weissman JS, Schumann K, Esensten JH, May AP, Ashworth A, Kupfer GM, Greeley SAW, Bacchetta R, Meffre E, Roncarolo MG, Romberg N, Herold KC, Ribas A, Leonetti MD, Marson A. PMID: 29995861; PMCID: PMC6239417.
      View in: PubMed   Mentions: 351     Fields:    Translation:HumansAnimalsCells
    18. 319 Developing a database to track critical parameters for clinical regulatory T cell manufacturing. Cytotherapy. 2018 May 1; 20(5):s108. Shy SB, Whitman WJ, Putnam PA, Lares LA, Tang TQ, Esensten EJ. .
      View in: Publisher Site   Mentions:
    19. 66 Low levels of EBV detected by PCR during manufacturing of clinical-grade stimulated B cells despite treatment with antiviral drugs. Cytotherapy. 2017 May 1; 19(5):s35. Lee LK, Tang TQ, Esensten EJ. .
      View in: Publisher Site   Mentions:
    20. Engineering Therapeutic T Cells: From Synthetic Biology to Clinical Trials. Annu Rev Pathol. 2017 Jan 24; 12:305-330. Esensten JH, Bluestone JA, Lim WA. PMID: 27959633; PMCID: PMC5557092.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    21. CD28 Costimulation: From Mechanism to Therapy. Immunity. 2016 05 17; 44(5):973-88. Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. PMID: 27192564; PMCID: PMC4932896.
      View in: PubMed   Mentions: 348     Fields:    Translation:HumansAnimalsCells
    22. Cdk8 deletion in the Apc(Min) murine tumour model represses EZH2 activity and accelerates tumourigenesis. J Pathol. 2015 Dec; 237(4):508-19. McCleland ML, Soukup TM, Liu SD, Esensten JH, de Sousa e Melo F, Yaylaoglu M, Warming S, Roose-Girma M, Firestein R. PMID: 26235356.
      View in: PubMed   Mentions: 32     Fields:    Translation:Animals
    23. Circulating proteolytic signatures of chemotherapy-induced cell death in humans discovered by N-terminal labeling. Proc Natl Acad Sci U S A. 2014 May 27; 111(21):7594-9. Wiita AP, Hsu GW, Lu CM, Esensten JH, Wells JA. PMID: 24821784; PMCID: PMC4040605.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    24. CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ T cell response. J Exp Med. 2013 Jul 29; 210(8):1603-19. Martínez-Llordella M, Esensten JH, Bailey-Bucktrout SL, Lipsky RH, Marini A, Chen J, Mughal M, Mattson MP, Taub DD, Bluestone JA. PMID: 23878307; PMCID: PMC3727315.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansAnimalsCells
    25. microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis. J Immunol. 2013 Aug 15; 191(4):1594-605. de Kouchkovsky D, Esensten JH, Rosenthal WL, Morar MM, Bluestone JA, Jeker LT. PMID: 23858035; PMCID: PMC4160833.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansAnimalsCells
    26. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev. 2011 May; 241(1):180-205. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. PMID: 21488898; PMCID: PMC3077803.
      View in: PubMed   Mentions: 188     Fields:    Translation:HumansAnimalsCells
    27. The miR-17-92 cluster is essential for regulatory T cell function in vivo (168.14). The Journal of Immunology. 2011 Apr 1; 186(1_Supplement):168.14-168.14. Jeker JL, De Kouchkovsky DD, Esensten EJ, Bluestone BJ. .
      View in: Publisher Site   Mentions:
    28. Transcriptional profile of CD28 costimulation and Dec1 relevance in T-cell activation (113.14). The Journal of Immunology. 2011 Apr 1; 186(1_Supplement):113.14-113.14. Martinez-Llordella MM, Esensten EJ, Bluestone BJ. .
      View in: Publisher Site   Mentions:
    29. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol. 2011 Apr 01; 186(7):3918-26. McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, Hulme MA, Hoffmüller U, Baron U, Olek S, Bluestone JA, Brusko TM. PMID: 21368230; PMCID: PMC3091943.
      View in: PubMed   Mentions: 219     Fields:    Translation:HumansCells
    30. Plasticity of Human Regulatory T Cells - Characterization of IFN-?-Producing Cells. Clinical Immunology. 2010 Jan 1; 135:s5-s6. McClymont MS, Putnam PA, Lee LM, Esensten EJ, Liu LW, Olek OS, Baron BU, Hoffmuller HU, Bluestone BJ, Brusko BT. .
      View in: Publisher Site   Mentions:
    31. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol. 2009 Oct; 5(10):560-5. Esensten JH, Wofsy D, Bluestone JA. PMID: 19798031; PMCID: PMC3086064.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansAnimalsCells
    32. T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J Immunol. 2009 Jul 01; 183(1):75-82. Esensten JH, Lee MR, Glimcher LH, Bluestone JA. PMID: 19535634; PMCID: PMC2732575.
      View in: PubMed   Mentions: 36     Fields:    Translation:AnimalsCells
    33. NFAT5 binds to the TNF promoter distinctly from NFATp, c, 3 and 4, and activates TNF transcription during hypertonic stress alone. Nucleic Acids Res. 2005; 33(12):3845-54. Esensten JH, Tsytsykova AV, Lopez-Rodriguez C, Ligeiro FA, Rao A, Goldfeld AE. PMID: 16027109; PMCID: PMC1175021.
      View in: PubMed   Mentions: 36     Fields:    Translation:AnimalsCells
    Jonathan's Networks
    Concepts (179)
    Derived automatically from this person's publications.
    Co-Authors (51)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department